Kiromic BioPharma Inc (KRBP) USD0.001
No change
- Add to watchlist
- This stock can be held in a
No change
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
No change
Business summary
Kiromic BioPharma, Inc. is a clinical-stage, fully integrated biotherapeutics company. The Company is engaged in developing a multi-indication allogeneic cell therapy platform that exploits the natural potency of Gamma Delta T-cells to target solid tumors. It is using its proprietary DIAMOND artificial intelligence (AI) 2.0 platform to discover targets for immuno-oncology. It has five clinical programs to study its key product candidates: Deltacel-01, Isocel combination, Alexis-ISO-1, Procel combination, and Alexis-PRO-1. Deltacelis its first allogeneic, off-the-shelf GDT cell-based product in Phase 1 clinical-stage. Its Procel and Isocel product candidates consist of allogeneic, engineered, off-the-shelf CAR-GDT cells, and they are in the preclinical development stage. Its Procel product candidate consists of engineered GDTs that target PD-L1. Isocel product candidate consists of engineered GDTs that target Mesothelin Isoform 2 positive tumors (Iso-Meso).
Contact details
Important dates
General stock information
- Short code:
- KRBP
- ISIN:
- US4976342042
- Market cap:
- $1.43 million
- Shares in issue:
- 1.55 million
- Sector:
- Biotechnology
- Exchange:
- Off Exchange
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.